BioSpace News Archive

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced that management will discuss full results from the ILLUMINATE-A Phase 3 study of lumasiran in a webcast conference call on Sunday, June 7, 2020 at 8:30 am ET.

The United States Food and Drug Administration has issued an emergency use authorization for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism.

ZEPOSIA is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced financial results for the three months ended March 31, 2020.

Zebra-Med’s AI1™platform is integrated in Apollo Radiology International’s dedicated COVID Reporting Center that reviews and analyzes all CT scans received across Apollo Hospitals around India.

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.

As part of its broad-ranging response to help protect frontline healthcare professionals during the COVID-19 pandemic, Honda engineers have developed new methods to use manufacturing equipment to produce critically needed face shields and have donated 70,000 face shields to healthcare workers at 305 medical facilities in 45 states to date with plans to donate another 60,000 in the coming days.

Calliditas Therapeutics AB will launch an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the United States and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States.

Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present virtually at the Jefferies 2020 Healthcare Conference on Thursday, June 4, at 4:30 p.m. ET. The Company’s presentation will be webcast live and archived on the “Events & Pres

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease.